廣東鴻圖(002101.SZ):減持期屆滿 部分股東合計減持1822.54萬股
格隆匯2月28日丨廣東鴻圖(002101.SZ)公佈,截至目前,減持計劃時間區間已屆滿。股東鈳迪投資、匯鑫投資、星瑜投資在本次減持計劃實施期限內以集中競價方式減持公司股份合計527.54萬股,減持股份的來源均為非公開發行股份(發行股份購買資產)。此外,股東四維爾集團、拓宜貿易以大宗交易方式分別減持公司股份1055萬股,240萬股,四維爾集團減持股份的來源為非公開發行股份(發行股份購買資產)、拓宜貿易減持股份的來源為大宗交易,其中四維爾集團減持的股份屬於一致行動人間的內部流轉。上述股東合計減持1822.54萬股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.